Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

996 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Negative Feedback Loop Regulates Integrin Inactivation and Promotes Neutrophil Recruitment to Inflammatory Sites.
McCormick B, Craig HE, Chu JY, Carlin LM, Canel M, Wollweber F, Toivakka M, Michael M, Astier AL, Norton L, Lilja J, Felton JM, Sasaki T, Ivaska J, Hers I, Dransfield I, Rossi AG, Vermeren S. McCormick B, et al. Among authors: norton l. J Immunol. 2019 Sep 15;203(6):1579-1588. doi: 10.4049/jimmunol.1900443. Epub 2019 Aug 19. J Immunol. 2019. PMID: 31427445 Free PMC article.
Localizing the lipid products of PI3Kγ in neutrophils.
Norton L, Lindsay Y, Deladeriere A, Chessa T, Guillou H, Suire S, Lucocq J, Walker S, Andrews S, Segonds-Pichon A, Rausch O, Finan P, Sasaki T, Du CJ, Bretschneider T, Ferguson GJ, Hawkins PT, Stephens L. Norton L, et al. Adv Biol Regul. 2016 Jan;60:36-45. doi: 10.1016/j.jbior.2015.10.005. Epub 2015 Nov 10. Adv Biol Regul. 2016. PMID: 26596865 Free PMC article.
Impaired B cell development in the absence of Krüppel-like factor 3.
Vu TT, Gatto D, Turner V, Funnell AP, Mak KS, Norton LJ, Kaplan W, Cowley MJ, Agenès F, Kirberg J, Brink R, Pearson RC, Crossley M. Vu TT, et al. J Immunol. 2011 Nov 15;187(10):5032-42. doi: 10.4049/jimmunol.1101450. Epub 2011 Oct 14. J Immunol. 2011. PMID: 22003205
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR. Portlock CS, et al. Among authors: norton l. Ann Oncol. 2004 Oct;15(10):1495-503. doi: 10.1093/annonc/mdh390. Ann Oncol. 2004. PMID: 15367410 Free article. Clinical Trial.
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Among authors: norton l. Clin Cancer Res. 2001 Dec;7(12):3934-41. Clin Cancer Res. 2001. PMID: 11751485 Clinical Trial.
996 results